Last reviewed · How we verify
trazodone hydrochloride prolonged-release tablet
At a glance
| Generic name | trazodone hydrochloride prolonged-release tablet |
|---|---|
| Sponsor | Lee's Pharmaceutical Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- One-Year Study of S1B-509 vs Placebo for Weight Loss (PHASE2)
- Bioavailability Study of 300 mg Trazodone Hydrochloride (New Polymer) vs. 300 mg Trazodone Hydrochloride (Contramid® Prolonged-release Tablets) Under Fasting Conditions (PHASE1)
- PK Study of Multi-dose Trazodone Hydrochloride Prolonged-released Tablets in Healthy Chinese (PHASE1)
- PK Study of Diet Effect of Trazodone Hydrochloride Prolonged-Released Tablets in Healthy Chinese (PHASE1)
- A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression (PHASE2, PHASE3)
- A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: